Article in American journal of physiology. Renal physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
12 authors.
Gizem YilmazDivision of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, Minnesota, United States.
Santu K SinghaDivision of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, Minnesota, United States.
Bansi SavaliyaDivision of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, Minnesota, United States.
Ahmed AbdelfattahDivision of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, Minnesota, United States.ORCID 0009-0005-7871-5772
Walaa ElsekailyDivision of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, Minnesota, United States.
Xiaohong XuDivision of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, Minnesota, United States.
Youwen ZhangDivision of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, Minnesota, United States.
Christian HannaDivision of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, Minnesota, United States.ORCID 0000-0002-9956-8696
Marie C HoganDivision of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, Minnesota, United States.ORCID 0000-0003-3031-8522
Alejandro R ChadeDepartment of Medical Pharmacology and Physiology, University of Missouri-Columbia, Columbia, Missouri, United States.
Alfonso EirinDivision of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, Minnesota, United States.ORCID 0000-0002-3864-9644
Maria V IrazabalDivision of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, Minnesota, United States.ORCID 0000-0002-9904-7778
Funding
Pilot and Feasibility CoreP30DK106912 · NIDDK · UNIVERSITY OF KANSAS MEDICAL CENTER · PI CALVET, JAMES P · 2015 to 2019
$5.5M
Role of homocysteine metabolism, endothelial function and microvascular rarefaction on renal disease severity and progression in ADPKDR01DK128017 · NIDDK · MAYO CLINIC ROCHESTER · PI IRAZABAL, MARIA V · 2021 to 2024
$2.4M
Role of mitochondrial microRNAs (mitomiRs) in endogenous renal repairR01DK129240 · NIDDK · MAYO CLINIC ROCHESTER · PI Alfonso Eirin · 2023 to 2026
$1.8M
A new large pre-clinical model of aging-related heart failure: a platform to develop new therapies for HFpEFR21AG084154 · NIA · UNIVERSITY OF MISSOURI-COLUMBIA · PI CHADE, ALEJANDRO ROBERTO · 2023 to 2023
$460k
Noninvasive evaluation of the intrarenal microvasculature in ADPKDR21DK129886 · NIDDK · MAYO CLINIC ROCHESTER · PI IRAZABAL, MARIA V · 2021 to 2022
$419k
HHS | National Institutes of Health (NIH) AG084154HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) DK106912HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) DK128017HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) DK129240NIA NIH HHS R21 AG084154NIDDK NIH HHS P30 DK106912NIDDK NIH HHS R01 DK128017NIDDK NIH HHS R01 DK129240NIDDK NIH HHS R21 DK129886U.S. Department of Defense (DOD) PR221810
6 · The paper itself
Abstract
The mechanisms contributing to progressive kidney damage in autosomal dominant polycystic kidney disease (ADPKD) remain unclear. Renal microvascular (MV) rarefaction plays an important role in kidney disease, but its natural history, underlying mechanisms, and contributions to renal disease progression in ADPKD remain unknown. We hypothesized that intrarenal MV rarefaction is present early on and is preceded by vascular transcriptional and metabolic changes.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Vascular transcriptional and metabolic changes precede progressive intrarenal microvascular rarefaction in autosomal dominant polycystic kidney disease. · full record | OpenQuestion